Benzinga | Aug 10, 2021 10:42AM EDT

Cantor Fitzgerald Maintains Overweight on Arena Pharmaceuticals, Lowers Price Target to $93

Cantor Fitzgerald analyst Alethia Young maintains Arena Pharmaceuticals (NASDAQ:ARNA) with a Overweight and lowers the price target from $100 to $93.